Ronald Stafford Watts
Directeur/Bestuurslid bij Wenkart Foundation
Profiel
Ronald Stafford Watts is currently the Director at Wenkart Foundation and a Non-Executive Director at Biosceptre International Ltd.
He previously worked as a Non-Executive Director at Biosceptre (Aust) Pty Ltd.
and as a Non-Executive Director at Energy Action Ltd.
from 2003 to 2017.
He holds a doctorate degree from the University of Cambridge and an undergraduate degree from The University of New South Wales.
Actieve functies van Ronald Stafford Watts
| Bedrijven | Functie | Begin |
|---|---|---|
| Wenkart Foundation | Directeur/Bestuurslid | - |
Biosceptre International Ltd.
 Biosceptre International Ltd. BiotechnologyHealth Technology Part of Biosceptre (Aust) Pty Ltd., Biosceptre International Ltd. is a biopharmaceutical company based in Babraham, UK. The British company is focused on developing their BRiDGECAR™ system, which combines nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies. The company's researchers are pioneers in cancer therapeutic development, with a vision of targeted treatment for millions of cancer patients across the world. The company's multi-targeted BRiDGECAR™ system has the potential to benefit a range of malignancies and make a drastic difference to the lives of millions of cancer patients. The company's advisory board includes Sir Gregory Winter, a 2018 Nobel Prize winner in Chemistry. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Ronald Stafford Watts
| Bedrijven | Functie | Einde |
|---|---|---|
| ENERGY ACTION LIMITED | Voorzitter | 12-11-2015 |
Biosceptre (Aust) Pty Ltd.
 Biosceptre (Aust) Pty Ltd. Pharmaceuticals: MajorHealth Technology Biosceptre (Aust) Pty Ltd. develops and commercializes antibody technologies for applications in the diagnosis and treatment of cancer. The company was founded in 2000 and is headquartered in North Ryde, Australia. | Directeur/Bestuurslid | - |
Opleiding van Ronald Stafford Watts
| The University of New South Wales | Undergraduate Degree |
| University of Cambridge | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ENERGY ACTION LIMITED | Commercial Services |
| Bedrijven in privébezit | 3 |
|---|---|
Biosceptre (Aust) Pty Ltd.
Biosceptre (Aust) Pty Ltd. Pharmaceuticals: MajorHealth Technology Biosceptre (Aust) Pty Ltd. develops and commercializes antibody technologies for applications in the diagnosis and treatment of cancer. The company was founded in 2000 and is headquartered in North Ryde, Australia. | Health Technology |
| Wenkart Foundation | |
Biosceptre International Ltd.
Biosceptre International Ltd. BiotechnologyHealth Technology Part of Biosceptre (Aust) Pty Ltd., Biosceptre International Ltd. is a biopharmaceutical company based in Babraham, UK. The British company is focused on developing their BRiDGECAR™ system, which combines nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies. The company's researchers are pioneers in cancer therapeutic development, with a vision of targeted treatment for millions of cancer patients across the world. The company's multi-targeted BRiDGECAR™ system has the potential to benefit a range of malignancies and make a drastic difference to the lives of millions of cancer patients. The company's advisory board includes Sir Gregory Winter, a 2018 Nobel Prize winner in Chemistry. | Health Technology |
